Covered recipient · General Payments record
JESSICA BAUMAN
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$4,182.50
2 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $4,182.50 | 2 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Aveo Pharmaceuticals, Inc. | $2,420.00 | 1 |
| Janssen Scientific Affairs, LLC | $1,762.50 | 1 |
Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JESSICA BAUMAN
NPI 1619139235 · CMS profile ID 579955
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
PHILADELPHIA, PA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1619139235?year=2025&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JESSICA BAUMAN, NPI 1619139235, CMS profile ID 579955. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1619139235?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). JESSICA BAUMAN, NPI 1619139235, CMS profile ID 579955. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1619139235?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- JESSICA BAUMAN, NPI 1619139235, CMS profile ID 579955, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1619139235?year=2025&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
2 matching records · $4,182.50 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–2 of 2.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Janssen Scientific Affairs, LLC | $1,762.50 | 12/18/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174190712 | CMS |
| Aveo Pharmaceuticals, Inc. | $2,420.00 | 10/23/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1199902646 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $662,530.20 | 43 |
| PY2024 | Recipient | $4,600.00 | 2 |
| PY2024 | Principal investigator | $597,434.60 | 56 |
| PY2023 | Recipient | $3,200.00 | 1 |
| PY2023 | Principal investigator | $615,260.38 | 77 |
| PY2022 | Principal investigator | $513,473.56 | 47 |
| PY2021 | Principal investigator | $536,056.62 | 88 |
| PY2020 | Recipient | $3,200.00 | 1 |
| PY2020 | Principal investigator | $550,482.65 | 74 |
| PY2019 | Principal investigator | $501,598.41 | 22 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
75 records in PY2020
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $350.00 | 12/17/2020 | Non-covered Recipient Entity FOX CHASE CANCER CENTER | A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial | No dispute reported | 06/30/2026 | 740743077 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $9,000.00 | 12/17/2020 | Non-covered Recipient Entity FOX CHASE CANCER CENTER | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 | No dispute reported | 06/30/2026 | 740743081 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $618.52 | 12/02/2020 | Non-covered Recipient Entity FOX CHASE CANCER CENTER | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 | No dispute reported | 06/30/2026 | 740743127 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,500.00 | 11/18/2020 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 734928979 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $195.20 | 11/09/2020 | Non-covered Recipient Entity FOX CHASE CANCER CENTER | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 | No dispute reported | 06/30/2026 | 740702593 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $271.17 | 11/09/2020 | Non-covered Recipient Entity FOX CHASE CANCER CENTER | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 | No dispute reported | 06/30/2026 | 740702595 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $15.64 | 11/09/2020 | Non-covered Recipient Entity FOX CHASE CANCER CENTER | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 | No dispute reported | 06/30/2026 | 740702597 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $32.55 | 11/09/2020 | Non-covered Recipient Entity FOX CHASE CANCER CENTER | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 | No dispute reported | 06/30/2026 | 740702599 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $47.25 | 11/09/2020 | Non-covered Recipient Entity FOX CHASE CANCER CENTER | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 | No dispute reported | 06/30/2026 | 740702601 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $65.89 | 11/09/2020 | Non-covered Recipient Entity FOX CHASE CANCER CENTER | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 | No dispute reported | 06/30/2026 | 740702603 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $78.75 | 11/09/2020 | Non-covered Recipient Entity FOX CHASE CANCER CENTER | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 | No dispute reported | 06/30/2026 | 740702605 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $15.75 | 11/09/2020 | Non-covered Recipient Entity FOX CHASE CANCER CENTER | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 | No dispute reported | 06/30/2026 | 740703085 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $20.75 | 11/09/2020 | Non-covered Recipient Entity FOX CHASE CANCER CENTER | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 | No dispute reported | 06/30/2026 | 740703087 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $22.44 | 11/09/2020 | Non-covered Recipient Entity FOX CHASE CANCER CENTER | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 | No dispute reported | 06/30/2026 | 740703089 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $253.23 | 11/09/2020 | Non-covered Recipient Entity FOX CHASE CANCER CENTER | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 | No dispute reported | 06/30/2026 | 740703125 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $62.25 | 11/09/2020 | Non-covered Recipient Entity FOX CHASE CANCER CENTER | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 | No dispute reported | 06/30/2026 | 740703127 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $63.00 | 11/09/2020 | Non-covered Recipient Entity FOX CHASE CANCER CENTER | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 | No dispute reported | 06/30/2026 | 740703129 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $30.92 | 11/09/2020 | Non-covered Recipient Entity FOX CHASE CANCER CENTER | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 | No dispute reported | 06/30/2026 | 740703131 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $35.16 | 11/09/2020 | Non-covered Recipient Entity FOX CHASE CANCER CENTER | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 | No dispute reported | 06/30/2026 | 740703133 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $6.50 | 11/09/2020 | Non-covered Recipient Entity FOX CHASE CANCER CENTER | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 | No dispute reported | 06/30/2026 | 740703169 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $62.25 | 11/09/2020 | Non-covered Recipient Entity FOX CHASE CANCER CENTER | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 | No dispute reported | 06/30/2026 | 740703171 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $76.00 | 11/09/2020 | Non-covered Recipient Entity FOX CHASE CANCER CENTER | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 | No dispute reported | 06/30/2026 | 740703173 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $78.75 | 11/09/2020 | Non-covered Recipient Entity FOX CHASE CANCER CENTER | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 | No dispute reported | 06/30/2026 | 740703175 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $1.95 | 11/09/2020 | Non-covered Recipient Entity FOX CHASE CANCER CENTER | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 | No dispute reported | 06/30/2026 | 740703177 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $136.00 | 11/09/2020 | Non-covered Recipient Entity FOX CHASE CANCER CENTER | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 | No dispute reported | 06/30/2026 | 740703217 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $8.55 | 11/09/2020 | Non-covered Recipient Entity FOX CHASE CANCER CENTER | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 | No dispute reported | 06/30/2026 | 740703223 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $8.85 | 11/09/2020 | Non-covered Recipient Entity FOX CHASE CANCER CENTER | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 | No dispute reported | 06/30/2026 | 740703225 |
| Principal investigator 1 | Innate Pharma, Inc | $26,009.80 | 11/06/2020 | Covered Recipient Teaching Hospital American Oncologic Hospial | Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | No dispute reported | 06/30/2026 | 714615829 |
| Principal investigator 1 | PFIZER INC. | $20,241.00 | 10/15/2020 | Covered Recipient Teaching Hospital American Oncologic Hospial | PHASE 12 STUDY OF PF06463922 AN ALKROS1 TYROSINE KINASE INHIBITOR IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS | No dispute reported | 06/30/2026 | 742906241 |
| Principal investigator 1 | PFIZER INC. | $27,918.00 | 10/15/2020 | Covered Recipient Teaching Hospital American Oncologic Hospial | PHASE 12 STUDY OF PF06463922 AN ALKROS1 TYROSINE KINASE INHIBITOR IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS | No dispute reported | 06/30/2026 | 742908155 |
| Principal investigator 1 | PFIZER INC. | $21,222.00 | 10/15/2020 | Covered Recipient Teaching Hospital American Oncologic Hospial | PHASE 12 STUDY OF PF06463922 AN ALKROS1 TYROSINE KINASE INHIBITOR IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS | No dispute reported | 06/30/2026 | 742908937 |
| Principal investigator 1 | PFIZER INC. | $19,941.00 | 10/15/2020 | Covered Recipient Teaching Hospital American Oncologic Hospial | PHASE 12 STUDY OF PF06463922 AN ALKROS1 TYROSINE KINASE INHIBITOR IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS | No dispute reported | 06/30/2026 | 742910133 |
| Principal investigator 1 | PFIZER INC. | $16,294.00 | 10/15/2020 | Covered Recipient Teaching Hospital American Oncologic Hospial | PHASE 12 STUDY OF PF06463922 AN ALKROS1 TYROSINE KINASE INHIBITOR IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS | No dispute reported | 06/30/2026 | 742910529 |
| Principal investigator 1 | PFIZER INC. | $34,553.00 | 10/15/2020 | Covered Recipient Teaching Hospital American Oncologic Hospial | PHASE 12 STUDY OF PF06463922 AN ALKROS1 TYROSINE KINASE INHIBITOR IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS | No dispute reported | 06/30/2026 | 742910895 |
| Principal investigator 1 | PFIZER INC. | $4,000.00 | 10/15/2020 | Covered Recipient Teaching Hospital American Oncologic Hospial | PHASE 12 STUDY OF PF06463922 AN ALKROS1 TYROSINE KINASE INHIBITOR IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS | No dispute reported | 06/30/2026 | 742911923 |
| Principal investigator 1 | PFIZER INC. | $9,098.00 | 10/15/2020 | Covered Recipient Teaching Hospital American Oncologic Hospial | PHASE 12 STUDY OF PF06463922 AN ALKROS1 TYROSINE KINASE INHIBITOR IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS | No dispute reported | 06/30/2026 | 742912071 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $1,541.00 | 10/13/2020 | Non-covered Recipient Entity FOX CHASE CANCER CENTER | A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial | No dispute reported | 06/30/2026 | 740742743 |
| Principal investigator 1 | Genentech, Inc. | $3,180.00 | 10/01/2020 | Non-covered Recipient Entity THE INSTITUTE FOR CANCER RESEARCH | ATEZOLIZUMAB VERSUS PLACEBO AS ADJUVANT THERAPY IN LOCALLY ADVANCED HEAD AND NECK CANCER | No dispute reported | 06/30/2026 | 743166311 |
| Principal investigator 1 | PFIZER INC. | $3,838.00 | 08/26/2020 | Covered Recipient Teaching Hospital American Oncologic Hospial | A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS DEFINITIVE RADIATION THERAPY VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN THE FRONTLINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK | No dispute reported | 06/30/2026 | 742907337 |
| Principal investigator 1 | PFIZER INC. | $3,838.00 | 08/26/2020 | Covered Recipient Teaching Hospital American Oncologic Hospial | A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS DEFINITIVE RADIATION THERAPY VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN THE FRONTLINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK | No dispute reported | 06/30/2026 | 742909979 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $12,500.00 | 08/10/2020 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 734905281 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 08/10/2020 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 734908715 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,000.00 | 08/10/2020 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 734908885 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,000.00 | 08/10/2020 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 734909695 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $670.00 | 08/10/2020 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 734910501 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,000.00 | 08/10/2020 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 734921445 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $250.00 | 08/10/2020 | Non-covered Recipient Entity INSTITUTE FOR CANCER RESEARCH | A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 | No dispute reported | 06/30/2026 | 734921447 |
| Recipient | PFIZER INC. | $3,200.00 | 08/07/2020 | Covered Recipient Physician | LORLATINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 742856131 |
| Principal investigator 1 | PFIZER INC. | $3,838.00 | 07/29/2020 | Covered Recipient Teaching Hospital American Oncologic Hospial | A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS DEFINITIVE RADIATION THERAPY VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN THE FRONTLINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK | No dispute reported | 06/30/2026 | 742907481 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $2,000.00 | 07/23/2020 | Non-covered Recipient Entity FOX CHASE CANCER CENTER | A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial | No dispute reported | 06/30/2026 | 740743259 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $2,000.00 | 07/22/2020 | Covered Recipient Teaching Hospital AMERICAN ONCOLOGIC HOSPIAL | A Phase III Randomized Trial of MK-3475 Versus Standard Treatment in Subjects with recurrent or metastatic head and neck cancer | No dispute reported | 06/30/2026 | 740779939 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $8,232.00 | 07/03/2020 | Covered Recipient Teaching Hospital AMERICAN ONCOLOGIC HOSPIAL | A Phase III Randomized Trial of MK-3475 Versus Standard Treatment in Subjects with recurrent or metastatic head and neck cancer | No dispute reported | 06/30/2026 | 740779891 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $10,788.80 | 07/03/2020 | Covered Recipient Teaching Hospital AMERICAN ONCOLOGIC HOSPIAL | A Phase III Randomized Trial of MK-3475 Versus Standard Treatment in Subjects with recurrent or metastatic head and neck cancer | No dispute reported | 06/30/2026 | 740779895 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $11,943.63 | 07/03/2020 | Covered Recipient Teaching Hospital AMERICAN ONCOLOGIC HOSPIAL | A Phase III Randomized Trial of MK-3475 Versus Standard Treatment in Subjects with recurrent or metastatic head and neck cancer | No dispute reported | 06/30/2026 | 740779937 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $350.00 | 06/18/2020 | Non-covered Recipient Entity FOX CHASE CANCER CENTER | A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial | No dispute reported | 06/30/2026 | 740743301 |
| Principal investigator 1 | PFIZER INC. | $9,551.10 | 06/17/2020 | Covered Recipient Teaching Hospital American Oncologic Hospial | A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS DEFINITIVE RADIATION THERAPY VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN THE FRONTLINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK | No dispute reported | 06/30/2026 | 742908261 |
| Principal investigator 1 | PFIZER INC. | $11,845.33 | 06/11/2020 | Covered Recipient Teaching Hospital American Oncologic Hospial | PHASE 12 STUDY OF PF06463922 AN ALKROS1 TYROSINE KINASE INHIBITOR IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS | No dispute reported | 06/30/2026 | 742908403 |
| Principal investigator 1 | Innate Pharma, Inc | $57,350.44 | 06/01/2020 | Covered Recipient Teaching Hospital American Oncologic Hospial | Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | No dispute reported | 06/30/2026 | 714615835 |
| Principal investigator 1 | Innate Pharma, Inc | $2,600.00 | 06/01/2020 | Covered Recipient Teaching Hospital American Oncologic Hospial | Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | No dispute reported | 06/30/2026 | 714615837 |
| Principal investigator 1 | PFIZER INC. | $3,838.00 | 05/27/2020 | Covered Recipient Teaching Hospital American Oncologic Hospial | A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS DEFINITIVE RADIATION THERAPY VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN THE FRONTLINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK | No dispute reported | 06/30/2026 | 742906633 |
| Principal investigator 1 | PFIZER INC. | $3,500.00 | 05/27/2020 | Covered Recipient Teaching Hospital American Oncologic Hospial | A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS DEFINITIVE RADIATION THERAPY VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN THE FRONTLINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK | No dispute reported | 06/30/2026 | 742910485 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $2,500.00 | 05/13/2020 | Non-covered Recipient Entity FOX CHASE CANCER CENTER | A Phase III Randomized Trial of MK-3475 Versus Standard Treatment in Subjects with recurrent or metastatic head and neck cancer | No dispute reported | 06/30/2026 | 740743211 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $350.00 | 05/12/2020 | Non-covered Recipient Entity FOX CHASE CANCER CENTER | A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial | No dispute reported | 06/30/2026 | 740743299 |
| Principal investigator 1 | Innate Pharma, Inc | $3,900.00 | 04/17/2020 | Covered Recipient Teaching Hospital American Oncologic Hospial | Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | No dispute reported | 06/30/2026 | 714615833 |
| Principal investigator 1 | PFIZER INC. | $3,838.00 | 04/07/2020 | Covered Recipient Teaching Hospital American Oncologic Hospial | A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS DEFINITIVE RADIATION THERAPY VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN THE FRONTLINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK | No dispute reported | 06/30/2026 | 742905839 |
| Principal investigator 1 | PFIZER INC. | $7,676.00 | 04/07/2020 | Covered Recipient Teaching Hospital American Oncologic Hospial | A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS DEFINITIVE RADIATION THERAPY VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN THE FRONTLINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK | No dispute reported | 06/30/2026 | 742908537 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $3,082.00 | 03/24/2020 | Non-covered Recipient Entity FOX CHASE CANCER CENTER | A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial | No dispute reported | 06/30/2026 | 740743249 |
| Principal investigator 1 | PFIZER INC. | $13,437.00 | 03/11/2020 | Covered Recipient Teaching Hospital American Oncologic Hospial | A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS DEFINITIVE RADIATION THERAPY VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN THE FRONTLINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK | No dispute reported | 06/30/2026 | 742910099 |
| Principal investigator 1 | PFIZER INC. | $10,953.00 | 03/11/2020 | Covered Recipient Teaching Hospital American Oncologic Hospial | A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS DEFINITIVE RADIATION THERAPY VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN THE FRONTLINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK | No dispute reported | 06/30/2026 | 742910905 |
| Principal investigator 1 | PFIZER INC. | $3,838.00 | 03/11/2020 | Covered Recipient Teaching Hospital American Oncologic Hospial | A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS DEFINITIVE RADIATION THERAPY VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN THE FRONTLINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK | No dispute reported | 06/30/2026 | 742912527 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $10,070.00 | 02/27/2020 | Non-covered Recipient Entity FOX CHASE CANCER CENTER | A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial | No dispute reported | 06/30/2026 | 740743247 |
| Principal investigator 1 | Innate Pharma, Inc | $10,937.70 | 02/14/2020 | Covered Recipient Teaching Hospital American Oncologic Hospial | Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | No dispute reported | 06/30/2026 | 714615831 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $12,454.36 | 02/06/2020 | Non-covered Recipient Entity Fox Chase Cancer Center-parent Account | Phase I II FIH ICOS Monotherapy Ipi Combination | No dispute reported | 06/30/2026 | 736759865 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $9,545.22 | 01/09/2020 | Non-covered Recipient Entity Institute For Cancer Research | Open-Label, Randomized Trial of Nivolumab (BMS-936558) plus Pemetrexed/Platinum or Nivolumab plus Ipilimumab (BMS-734016) vs Pemetrexed plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects with Epidermal Growth Factor Receptor (EGFR) Mutation, T790M | No dispute reported | 06/30/2026 | 736760287 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $104,912.95 | 01/06/2020 | Covered Recipient Teaching Hospital American Oncologic Hospial | Phase I II FIH ICOS Monotherapy Ipi Combination | No dispute reported | 06/30/2026 | 736758581 |